Tezosentan. Actelion/Genentech.
Tezosentan is an endothelin receptor antagonist in development by Actelion Ltd and Genentech Inc for the potential treatment of cardiovascular disorders, including acute heart failure (AHF) and congestive heart failure. Actelion has conducted a phase III study of tezosentan in AHF patients, however, following disappointing trial results a new phase III study in AHF was planned using lower doses of the compound. By January 2003, Actelion anticipated that the first results of a two-year phase III study evaluating mortality/morbidity would be available by early 2005.
UO Cardiologia, Ospedale Civile di Legnano 20025 Legano, Milan, Italy.
Enrico
E
Rossetti
Stefano
S
De Servi
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism; D002986:Clinical Trials as Topic; D065128:Endothelin Receptor Antagonists; D006801:Humans; D011725:Pyridines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D044022:Receptor, Endothelin A; D013329:Structure-Activity Relationship; D013777:Tetrazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D065128:Endothelin Receptor Antagonists; D011725:Pyridines; D044022:Receptor, Endothelin A; D013777:Tetrazoles; D014665:Vasodilator Agents; C120582:tezosentan